echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > J Thorac Oncol: The efficacy of small cell lung cancer (SCLC) in preventing intracranial irradiation to avoid or not avoid hippocampal structure (HA): a randomized III clinical trial (NCT01780675)

    J Thorac Oncol: The efficacy of small cell lung cancer (SCLC) in preventing intracranial irradiation to avoid or not avoid hippocampal structure (HA): a randomized III clinical trial (NCT01780675)

    • Last Update: 2021-05-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Patients with small cell lung cancer (SCLC) have a high probability of brain metastasis (BM).


    Patients with small cell lung cancer (SCLC) have a high probability of brain metastasis (BM).


    Therefore, foreign scholars have conducted relevant research and published relevant research results in the Journal of Thoracic Oncology.


    The study included 168 patients from 10 centers in the Netherlands and Belgium from April 2013 to March 2018.


    The study included 168 patients from 10 centers in the Netherlands and Belgium from April 2013 to March 2018.


    A total of 102 patients were included in the analysis when the primary study endpoint was reached, including 46 patients in the PCI group and 56 patients in the HA-PCI group.


    Clinical characteristics of the two groups

    Clinical characteristics of the two groups

    Two groups of HVLT-R rate

    Two groups of HVLT-R rate

    Cumulative brain metastasis rate in 2 years: PCI group is 20% (95%CI: 12%-29%), and HA-PCI group is 16% (95%CI: 7%-24%).


    Cumulative brain metastasis rate in 2 years: PCI group is 20% (95%CI: 12%-29%), and HA-PCI group is 16% (95%CI: 7%-24%).


    The incidence of brain metastases in the two groups

    The incidence of brain metastases in the two groups

    At the time of data cut-off, 102 of the 168 patients had died (49 in the HA-PCI group and 53 in the PCI group).


    At the time of data cut-off, 102 of the 168 patients had died (49 in the HA-PCI group and 53 in the PCI group).


    Comparison of median OS

     Comparison of median OS

    In summary, the prevention of intracranial irradiation of small cell lung cancer (SCLC) did not avoid hippocampal irradiation (HA-PCI) and did not lead to a significant decline in neurocognitive function, and the rate of brain metastasis within 2 years did not increase significantly.


    In summary, the prevention of intracranial irradiation of small cell lung cancer (SCLC) did not avoid hippocampal irradiation (HA-PCI) and did not lead to a significant decline in neurocognitive function, and the rate of brain metastasis within 2 years did not increase significantly.


    Original source:

    José SA Belderbos, Dirk KM De Ruysscher, Katrien De Jaeger, et al.


    José SA Belderbos, Dirk KM De Ruysscher, Katrien De Jaeger, et al.
    Phase 3 Randomized Trial of Prophylactic Cranial Irradiation With or Without Hippocampus Avoidance in SCLC (NCT01780675).
    J Thorac Oncol.
    2021 May;16(5):840-849 .
    doi: 10.
    1016/j.
    jtho.
    2020.
    12.
    024.
    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.